Loading clinical trials...
Loading clinical trials...
Alzheimer's Disease and Faecal Microbiota Transplantation
The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.
Alzheimer's disease (AD) is the most common cause of dementia. Studies suggest that the gut flora may play a role in the development and/or progression of AD. The gut flora is found to be different in AD compared to healthy individuals. There is also support for a link between the gut flora and diseases affecting the brain, including AD. Stool transplantation is an established medical treatment for Clostridioides difficile infections by restoring the balance of the gut flora. In this study, gut flora (a stool solution) is transferred from a healthy individual to an individual with AD. The stool transplantation is given during a colonoscopy examination of the large bowel.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
January 1, 2026
Primary Completion Date
June 1, 2026
Completion Date
January 1, 2027
Last Updated
January 14, 2026
10
ESTIMATED participants
Biological: Preprocessed thawed donor FMT
BIOLOGICAL
Lead Sponsor
University Hospital of North Norway
Collaborators
NCT07262645
NCT07279103
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07208734